# IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma

> **NCT07481721** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Ming Yang** · enrollment: 24 (estimated)

## Conditions studied

- Recurrent Malignant Glioma

## Interventions

- **BIOLOGICAL:** IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody

## Key facts

- **NCT ID:** NCT07481721
- **Lead sponsor:** Ming Yang
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481721, "IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody for Recurrent Malignant Glioma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT07481721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*